{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T22:55:28Z","timestamp":1789772128724,"version":"4.0.1"},"reference-count":21,"publisher":"Japanese Society of Internal Medicine","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2022,9,1]]},"DOI":"10.2169\/internalmedicine.8919-21","type":"journal-article","created":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T22:08:40Z","timestamp":1645222120000},"page":"2619-2623","source":"Crossref","is-referenced-by-count":11,"title":["Atezolizumab-induced Encephalitis in a Patient with Hepatocellular Carcinoma: A Case Report and Literature Review"],"prefix":"10.2169","volume":"61","author":[{"given":"Tomoyuki","family":"Satake","sequence":"first","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Maruki","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Kubo","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology, National Cancer Center Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masamichi","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Ohba","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikuni","family":"Nagashio","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Kondo","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susumu","family":"Hijioka","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chigusa","family":"Morizane","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Ueno","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuji","family":"Okusaka","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Kao JC, Liao B, Markovic SN, et al. Neurological complications associated with anti-programmed death 1 (PD-1) antibodies. JAMA Neurol 74: 1216-1222, 2017.","DOI":"10.1001\/jamaneurol.2017.1912"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Kim A, Keam B, Cheun H, et al. Immune-checkpoint-inhibitor-induced severe autoimmune encephalitis treated by steroid and intravenous immunoglobulin. J Clin Neurol 15: 259-261, 2019.","DOI":"10.3988\/jcn.2019.15.2.259"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Williams TJ, Benavides DR, Patrice KA, et al. Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer. JAMA Neurol 73: 928-933, 2016.","DOI":"10.1001\/jamaneurol.2016.1399"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4. Rittmeyer A, Barlesi F, Waterkamp D, et al.; OAK Study Group. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389: 255-265, 2017.","DOI":"10.1016\/S0140-6736(16)32517-X"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Socinski MA, Jotte RM, Cappuzzo F, et al. IMpower150 study group. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med 14: 2288-2301, 2018.","DOI":"10.1056\/NEJMoa1716948"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Martins F, Sofiya L, Sykiotis GP, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 16: 563-580, 2019.","DOI":"10.1038\/s41571-019-0218-0"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Levine JJ, Somer RA, Hosoya H, et al. Atezolizumab-induced encephalitis in metastatic bladder cancer: a case report and review of the literature. Clin Genitourin Cancer 15: e847-e849, 2017.","DOI":"10.1016\/j.clgc.2017.03.001"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Laserna A, Tummala S, Patel N, et al. Atezolizumab-related encephalitis in the intensive care unit: case report and review of the literature. SAGE Open Med 6: 2050313X18792422, 2018.","DOI":"10.1177\/2050313X18792422"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Dalakas MC. Neurological complications of immune checkpoint inhibitors: what happens when you 'take the brakes off' the immune system. Ther Adv Neurol Disord 11: 1756286418799864, 2018.","DOI":"10.1177\/1756286418799864"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Cuzzubbo S, Javeri F, Tissier M, et al. Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur J Cancer 73: 1-8, 2017.","DOI":"10.1016\/j.ejca.2016.12.001"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Arakawa M, Yamazaki M, Toda Y, et al. Atezolizumab-induced encephalitis in metastatic lung cancer: a case report and literature review. eNeurologicalSci 14: 49-50, 2019.","DOI":"10.1016\/j.ensci.2018.12.001"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Yamaguchi Y, Nagasawa H, Katagiri Y, et al. Atezolizumab-associated encephalitis in metastatic lung adenocarcinoma: a case report. J Med Case Rep 14: 88, 2020.","DOI":"10.1186\/s13256-020-02411-y"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Chang H, Shin YW, Keam B, et al. HLA-B27 association of autoimmune encephalitis induced by PD-L1 inhibitor. Ann Clin Transl Neurol 7: 2243-2250, 2020.","DOI":"10.1002\/acn3.51213"},{"key":"14","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1212\/01.WNL.0000144274.12174.CB","volume":"63","author":"H Tada","year":"2004","unstructured":"14. Tada H, Takanashi J, Barkovich AJ, et al. Clinically mild encephalitis\/encephalopathy with a reversible splenial lesion. Neurology 63: 1854-1858, 2004.","journal-title":"Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/0028-3878","issn-type":"print"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Conry RM, Sullivan JC, Nabors LB 3rd. Ipilimumab-induced encephalopathy with a reversible splenial lesion. Cancer Immunol Res 3: 598-601, 2015.","DOI":"10.1158\/2326-6066.CIR-15-0035"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Stuby J, Herren T, Schwegler Naumburger G, et al. Immune checkpoint inhibitor therapy-associated encephalitis: a case series and review of the literature. Swiss Med Wkly 150: w20377, 2020.","DOI":"10.4414\/smw.2020.20377"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Gill A, Perez MA, Perrone CM, et al. A case series of PD-1 inhibitor-associated paraneoplastic neurologic syndromes. J Neuroimmunol 334: 576980, 2019.","DOI":"10.1016\/j.jneuroim.2019.576980"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Madhavan AA, Carr CM, Morris PP, et al. Imaging review of paraneoplastic neurologic syndromes. AJNR Am J Neuroradiol 41: 2176-2187, 2020.","DOI":"10.3174\/ajnr.A6815"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Chang PE, Ong WC, Lui HF, et al. Epidemiology and prognosis of paraneoplastic syndromes in hepatocellular carcinoma. ISRN Oncol 2013: 684026, 2013.","DOI":"10.1155\/2013\/684026"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Matsui T, Hori Y, Nagano H, et al. Poorly differentiated hepatocellular carcinoma accompanied by anti-Hu antibody-positive paraneoplastic peripheral neuropathy. Pathol Int 65: 388-392, 2015.","DOI":"10.1111\/pin.12304"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Graus F, Vogrig A, Mu\u00f1iz-Castrillo S, et al. Updated diagnostic criteria for paraneoplastic neurologic syndromes. Neurol Neuroimmunol Neuroinflamm 8: e1014, 2021.","DOI":"10.1212\/NXI.0000000000001014"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/17\/61_8919-21\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T03:33:57Z","timestamp":1662176037000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/17\/61_8919-21\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,1]]},"references-count":21,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.8919-21","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,1]]},"article-number":"8919-21"}}